Sai-Hong IIgnatiusOuMDPhD

PubMed

• A pragmatic guide for management of adverse events associated with lorlatinib.
  Geoffrey Liu, Julien Mazieres, Jan Stratmann, Tony Mok, Mary Grizzard, Yasushi Goto, Enriqueta Felip, Benjamin J Solomon, Sai-Hong Ignatius Ou, Todd M Bauer> ;Lung Cancer. 2024 Mar 15
• Chemotherapy and Osimertinib Combination Should Be the First-Line Treatment for All Advanced EGFR+ NSCLC.
  Lanyi Nora Chen, Alexandria T M Lee, Misako Nagasaka, Sai-Hong Ignatius Ou> ;Journal of Thoracic Oncology. 2024 Mar 1
• MARIPOSA-2: Is the treatment worse than the disease?
  Lee, A., Ou, S.> ;Med. 2024 Feb 9
• Taletrectinib for the treatment ofpositive non-small cell lung cancer: a drug evaluation of phase I and II data.
  Nagasaka, M., Brazel, D., Ou, S.> ;Expert Opinion on Investigational Drugs. 2024 Feb 1
• Overcoming Central β-Sheet #6 (Cβ6)Mutation (L1256F),Mutations and Short Forms ofandSplice Variants are the Unmet Need That a Re-Imagined 5th-Generation (5G) ALK TKI M...
  Alexandria T M Lee, Sai-Hong Ignatius Ou> ;Lung Cancer. 2024 Jan 1
• Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer.
  Chen, J., Bearz, A., Kim, D., Mamdani, H., Bauman, J., Chiari, R., Ou, S., Solomon, B., Soo, R., Felip, E., Shaw, A., Thurm, H., Clancy, J., Lee, K., O'Gorman, M., Tan...> ;Clinical Pharmacokinetics. 2024 Feb 1
• 1 citations
  Comprehensive Review of ROS1 Tyrosine Kinase Inhibitors-Classified by Structural Designs and Mutation Spectrum (Solvent Front Mutation [G2032R] and Central β-Sheet 6 [...
  Ou, S., Hagopian, G., Nagasaka, M., Zhang, S.> ;Journal of Thoracic Oncology. 2023 Dec 7
• 1 citations
  Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial.
  Desai, J., Alonso, G., Kim, S., Cervantes, A., Karasic, T., Medina, L., Shacham-Shmueli, E., Cosman, R., Falcon, A., Gort, E., Guren, T., Massarelli, E., Miller, W., P...> ;Nature Medicine. 2024 Jan 1
• Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non-Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemo...
  Prawitz, T., Lin, H., Hong, J., Tan, M., Proskorovsky, I., Hernandez, L., Jin, S., Zhang, P., Lin, J., Nguyen, D., Ou, S., Patel, J., Neal, J.> ;Clinical Lung Cancer. 2023 Dec 4
• 1 citations
  Plasma Genotyping From the CROWN, ALTA-1L, and ALEX Trials: Can We Speak With One Voice on What to Test, How to Test, When to Test, and for What Purpose?
  Jii Bum Lee, Sai-Hong Ignatius Ou> ;Journal of Thoracic Oncology. 2023 Nov 1
• Osimertinib tolerance in a patient with Stevens Johnson syndrome during osimertinib therapy after treatment with pembrolizumab.
  Garo Hagopian, Linda Doan, Benjamin J Lee, Nathan W Rojek, Janellen Smith, Sai-Hong Ignatius Ou, Yesim Yilmaz Demirdag, Misako Nagasaka, Lopez, M.> ;Allergy, Asthma, and Clinical Immunology. 2023 Oct 28
• Pan-tumor survey of ROS1 fusions detected by next-generation RNA and whole transcriptome sequencing.
  Misako Nagasaka, Yasmine Baca, Joanne Xiu, Jorge Nieva, Ari Vanderwalde, Jeffrey J Swensen, David Spetzler, Wolfgang Michael Korn, Luis E Raez, Stephen V Liu, Sai-Hong...> ;BMC Cancer. 2023 Oct 18
• 3 citations
  Real-World Response and Outcomes in Patients With NSCLC WithExon 20 Insertion Mutations.
  Sai-Hong Ignatius Ou, Huamao M Lin, Jin-Liern Hong, Yu Yin, Shu Jin, Jianchang Lin, Minal Mehta, Danny Nguyen, Joel W Neal> ;JTO Clinical and Research Reports. 2023 Oct 1
• Reply to Jayaraj et al. "Clinical Validity and Conceptual Interpretation of the Meta-Analysis on the Efficacy of LDCT Lung Cancer Screening in Never-Smokers".
  Natthaya Triphuridet, Yanfei Gao, Sai-Hong Ignatius Ou> ;Journal of Thoracic Oncology. 2023 Oct 1
• Response to "NGS, the New Global Standard?"
  Sai-Hong Ignatius Ou, Jin-Liern Hong, Petros Christopoulos, Huamao M Lin, Sylvie Vincent, Eric N Churchill, Junpei Soeda, Daniel Kazdal, Michael Thomas, Albrecht Stenz...> ;Journal of Thoracic Oncology. 2023 Oct 1
• 10 citations
  Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial.
  Byoung Chul Cho, Dong-Wan Kim, Alexander I Spira, Jorge E Gomez, Eric B Haura, Sang-We Kim, Rachel E Sanborn, Eun Kyung Cho, Ki Hyeong Lee, Anna Minchom, Jong-Seok Lee...> ;Nature Medicine. 2023 Oct 1
• 1 citations
  Letter to Editor. Re "de Leeuw SP, et al. Analysis of Serious Weight Gain in Patients Using Alectinib for ALK Positive Lung Cancer," Semaglutide a Potential Treatment ...
  Alexandria T M Lee, Sai-Hong Ignatius Ou, Aaron Lisberg> ;Journal of Thoracic Oncology. 2023 Sep 1
• Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced- or-Rearranged NSCLC: A Brief Report.
  Rohit Thummalapalli, Noura J Choudhury, Fiona Ehrich, Tyler Beardslee, Danielle Brazel, Shannon S Zhang, Shelby Merchant, Monica F Chen, Glenn Heller, Suresh S Ramalin...> ;JTO Clinical and Research Reports. 2023 Aug 1
• 2 citations
  Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subset.
  Misako Nagasaka, Danielle Brazel, Yasmine Baca, Joanne Xiu, Mohammed Najeeb Al-Hallak, Chul Kim, Jorge Nieva, Jeffrey J Swensen, David Spetzler, Wolfgang Michael Korn,...> ;Translational Oncology. 2023 Oct 1
• 2 citations
  Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non-Small Cell Lung Cancer Patients.
  Cloud P Paweletz, Grace A Heavey, Yanan Kuang, Emily Durlacher, Thian Kheoh, Richard C Chao, Alexander I Spira, Konstantinos Leventakos, Melissa L Johnson, Sai-Hong Ig...> ;Clinical Cancer Research. 2023 Aug 15
• 2 citations
  Reply to "Smeltzer MP, Liao W, Faris NR, et al. Potential Impact of Criteria Modifications on Race and Sex Disparities in Eligibility for Lung Cancer Screening. J Thor...
  Natthaya Triphuridet, Sai-Hong Ignatius Ou> ;Journal of Thoracic Oncology. 2023 Jun 1
• 3 citations
  From preclinical efficacy to 2022 (36.7 months median follow -up) updated CROWN trial, lorlatinib is the preferred 1st-line treatment of advanced ALK+ NSCLC.
  Sai-Hong Ignatius Ou, Alexandria T M Lee, Misako Nagasaka> ;Critical Reviews in Oncology/hematology. 2023 Jul 1
• Selpercatinib as the Guardian of the Central Nervous System for Patients With RET Fusion-Positive NSCLC?
  Sally C M Lau, Sai-Hong Ignatius Ou> ;Journal of Thoracic Oncology. 2023 May 1
• 2 citations
  Indirect comparison of mobocertinib and real-world therapies for pre-treated non-small cell lung cancer with EGFR exon 20 insertion mutations.
  Petros Christopoulos, Thibaud Prawitz, Jin-Liern Hong, Huamao M Lin, Luis Hernandez, Shu Jin, Min Tan, Irina Proskorovsky, Jianchang Lin, Pingkuan Zhang, Jyoti D Patel...> ;Lung Cancer. 2023 May 1
• Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison.
  Sai-Hong I Ou, Huamao M Lin, Jin-Liern Hong, Yu Yin, Shu Jin, Jianchang Lin, Minal Mehta, Pingkuan Zhang, Danny Nguyen, Joel W Neal> ;Lung Cancer. 2023 May 1
• Join now to see all

Lectures

• Liquid Biopsy to Identify Actionable Genomic Alterations 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/5/2018
• Medical Oncologist’s Perspective 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer (NSCLC). 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
• Characterization of 1,233 NSCLCs with non-del19/L858R EGFR mutations (EGFRm) using comprehensive genomic profiling (CGP). 
  2018 ASCO Annual Meeting - Chicago, Illinois - Chicago, Illinois- Chicago, Illinois - 06/3/2018
• Join now to see all